Actively Recruiting
Minimally Invasive Coronary Artery Bypass Supported by Cangrelor
Led by Cardiocentro Ticino · Updated on 2026-04-14
30
Participants Needed
1
Research Sites
189 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to find out whether it is safe and practical to perform MIDCAB surgery (a minimally invasive heart bypass procedure) while patients receive a continuous cangrelor infusion during the operation. Cangrelor is a medicine that helps prevent blood clots and works quickly through a vein drip. The study compares patients receiving cangrelor during surgery to patients who had the same surgery in the past while on aspirin, with or without cangrelor given beforehand. Study Question: Can MIDCAB surgery be safely performed under cangrelor infusion, without increasing the risk of bleeding or other complications? Hypothesis: Using cangrelor during MIDCAB surgery is safe and feasible, and it provides effective protection against blood clots during the procedure. This study will help doctors understand whether intraoperative cangrelor can improve patient safety and outcomes in minimally invasive heart surgery.
CONDITIONS
Official Title
Minimally Invasive Coronary Artery Bypass Supported by Cangrelor
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Undergoing coronary artery bypass graft (CABG) with internal mammary artery (IMA) to left anterior descending artery (LAD) graft using MIDCAB technique
- Signed informed consent (prospective arm only)
You will not qualify if you...
- Recent administration of fibrinolytics or GP IIb/IIIa inhibitors
- Previous intracranial hemorrhage
- Known bleeding diathesis (bleeding disorder)
- Undergoing both percutaneous coronary intervention (PCI) and MIDCAB simultaneously
- Severe kidney or liver disease
- Pregnancy or breastfeeding
- Unconsciousness (prospective arm only)
- Known allergy to cangrelor (prospective arm only)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Istituto Cardiocentro Ticino
Lugano, Ch/ti, Switzerland, 6900
Actively Recruiting
Research Team
M
Marco Valgimigli, Prof Dr Med
CONTACT
S
Servizio di Ricerca Cardiovascolare Cardiocentro
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here